FindTrial
Sign In

To study the Effects of the Systane Ultra eye drops in the treatment of Dry eye disease.

Effect of Management of Dry eye with Systane Ultra on Health-Related Quality Of Life (HRQOL) - NA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052176
Enrollment
48
Registered
2023-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H00-H59- Diseases of the eye and adnexa

Interventions

Intervention1: Polyethylene glycol 400, Propylene glycol Ophthalmic Solution Systane ULTRA: Dry eye disease treatment,1 drop (30microlitre) 4times/day for 1 month via ocular cul-de-sac Control Interv

Sponsors

Alcon Laboratories Ind Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects of 18- 50 years with mild-moderate dry eye and having Ocular Surface Disease Index(OSDI) Questionnaire score of 13-32

Exclusion criteria

Exclusion criteria: 1.Subjects diagnosed to have severe dry eye(OSDI >32) 2.Subjects who have undergone cataract surgery, refractive surgery, or any other ocular surgery 3.Subjects who have used contact lenses within the last 6 months. 4.Subjects who are on treatment with other artificial tear products, other topical drops or previously diagnosed with other ocular

Design outcomes

Primary

MeasureTime frame
Improvement in symptom scoreTimepoint: 1 MONTH—

Secondary

MeasureTime frame
Improvement in tear film parameters (Schirmerâ??s, NIBUT, Corneal staining scores and keratograph)Timepoint: 1 MONTH—

Countries

India

Contacts

Public ContactDr Rachapalle Reddi Sudhir

Ophthalmologist, Sankara Nethralaya

drrrs@snmail.org

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026